AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101.

December 12, 2022

The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded a 99-percent failure rate. Trials for these drugs — mostly expensive antibody-infusion based therapies — focus on treating people with Alzheimer’s early on. However, there are currently six million Americans already living with Alzheimer’s, and the majority are too far along in their Alzheimer’s journey to qualify for the trials.

Read the full article here.